Papulopustular eruption after intravitreal bevacizumab (Avastin).
Amselem
Luis
L
Diaz-Llopis
Manuel
M
Garcia-Delpech
Salvador
S
Montero
Javier
J
Palomares
Paula
P
Cervera
Enrique
E
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab